Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 9/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.62 |
| ▸ | PDE4A | P27815 | 5/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2906837 | 1.00 | PDE4D (0.62) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL7443689 | 0.89 | PDE4A (0.62) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7443694 | 0.89 | PDE4A (0.62) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL8466564 | 0.89 | PDE4A (0.62) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7450391 | 0.86 | PDE4A (0.61) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL8466408 | 0.86 | PDE4A (0.61) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7450388 | 0.86 | PDE4A (0.61) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL20363452 | 0.86 | PDE4D (0.62) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17003829 | 0.83 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17003826 | 0.83 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017480-B2 | Compounds having a selective PDE4D inhibiting activity | UNIVERSITA DEGLI STUDI DI GENOVA (IT) | 2018-07-10 | — | — | US | disclosed |
| EP-3105206-A1 | NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY | Universita' degli Studi di Genova (IT) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355489-A1 | NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY | 2016-12-08 | — | — | US | disclosed |
| WO-2015121212-A1 | NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY | UNIVERSITÀ DEGLI STUDI DI GENOVA (IT) | 2015-08-20 | — | — | WO | disclosed |
| EP-2907806-A1 | New compounds as selective PDE4D inhibitors | UNIVERSITA DEGLI STUDI DI GENOVA (IT) | 2015-08-19 | — | — | EP | disclosed |
| US-7825147-B2 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-02 | — | — | US | disclosed |
| EP-1879884-B1 | AZOLE-BASED PHOSPHODIESTERASE INHIBITORS | RANBAXY LAB LTD (IN) | 2010-08-25 | — | — | EP | disclosed |
| US-7750009-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20090048247-A1 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE - IV | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| EP-1879884-A1 | AZOLE-BASED PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | disclosed |
| EP-1169321-A2 | PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY | Euro-Celtique S.A. (LU) | 2002-01-09 | — | — | EP | disclosed |
| US-6319928-B1 | ASTHMA, ALLERGIES, INFLAMMATION,DEPRESSION, DEMENTIA, ALZHEIMER'S DISEASE, VASCULAR AND MULTI-IN-FARCT DEMENTIA AND DISEASE CAUSED BY HUMAN IMMUNODEFICIENCY VIRUS TREATMENT; EFFICIENCY AND SELECTIVITY | EURO-CELTIQUE, S.A. (LU) | 2001-11-20 | — | — | US | disclosed |
| US-6294541-B1 | ENZYME INHIBITORS USING PURINE COMPOUNDS AS ANTIHISTAMINES | EURO-CELTIQUE S.A. (LU) | 2001-09-25 | — | — | US | disclosed |
| US-6251897-B1 | TREATING DERMATITIS, ASTHMA | NIKKEN CHEMICALS CO., LTD (JP) | 2001-06-26 | — | — | US | disclosed |
| WO-2000059449-A2 | PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY | EURO-CELTIQUE S.A. (LU) | 2000-10-12 | — | — | WO | disclosed |
| US-5939422-A | AN ENZYME INHIBITOR AS BRONCHODILATOR, RELAXANTS, ANTIINFLAMMATORY AGENT FOR TREATING ASTHMA, ALLERGIES, INFLAMMATION, DEPRESSION, DEMENTIA, DISEASES ASSOCIATED WITH ABNORMAL HIGH LEVEL OF CYTOKINE | EURO-CELTIQUE, S.A. (LU) | 1999-08-17 | — | — | US | disclosed |
| EP-0705265-B1 | NOVEL CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITION ACTIVITY | EURO CELTIQUE SA (LU) | 1999-07-28 | — | — | EP | disclosed |
| EP-0928789-A1 | 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ONE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0916672-A1 | 6-Amino purine derivatives having PDE-IV inhibition activity and intermediates | Euroceltique S.A. (LU) | 1999-05-19 | — | — | EP | disclosed |
| EP-0916673-A1 | 6-Amino purine derivatives having PDE-IV inhibition activity | Euroceltique S.A. (LU) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355489-A1 | NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY | PDE4A, PDE4D, PDE4B | PDE4D 2/4885PDE4B 3/4885PDE4A 1/4885 |
| US-20090048247-A1 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE - IV | PDE3B, PDE4A, PDE3A | PDE4D 11/4885PDE4B 4/4885PDE4A 2/4885 |
| US-10017480-B2 | Compounds having a selective PDE4D inhibiting activity | PDE4A, PDE4D, PDE2A | PDE4D 2/4885PDE4B 4/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.